LCP
PBYI icon

Lamond Capital Partners’s Puma Biotechnology PBYI Stock Holding History

Lamond Capital Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-220,780
Closed -$17.3M – 4
2015
Q4 		$17.3M Buy
+220,780
New +$17.3M 25.87% 3
2015
Q1 		– Sell
-55,005
Closed -$10.4M – 16
2014
Q4 		$10.4M Buy
+55,005
New +$12.2M 6.82% 7

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lamond Capital Partners's PBYI Position: Q1 2016 in Review

Lamond Capital Partners sold out of Puma Biotechnology (PBYI) in Q1 2016, closing a stake of 220,780 shares — an estimated $17.3M sold.

Lamond Capital Partners first reported a position in PBYI in Q4 2014 and held it in 2 quarters. The position peaked at $17.3M in Q4 2015. 119 funds tracked by Wall St. Rank hold PBYI as of Q1 2016.

  • Lamond Capital Partners reported no remaining Puma Biotechnology position as of Q1 2016 after selling out during the quarter.
  • Lamond Capital Partners sold 220,780 Puma Biotechnology shares in Q1 2016, an estimated $17.3M.
  • Lamond Capital Partners first reported a position in Puma Biotechnology in Q4 2014 and held it in 2 quarters.
  • Lamond Capital Partners's Puma Biotechnology position peaked at $17.3M in Q4 2015.
  • 119 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2016.

Based on Lamond Capital Partners's 13F filing for Q1 2016, filed 5 May 2016.